Protective Effect of Vinpocetine Against Hepatotoxicity of Doxorubicin

Objective: Doxorubicin is an anti-cancer drug which induces multi-organs disorders, Doxorubicin's conventional use which result in development of cardiotoxicity, nephrotoxicity, and hepatotoxicity problems. This project was intended to explore the hepatoprotective impact of vinpocetine which is an alkaloid that has antioxidative and anti-inflammatory purposes, against doxorubicin induced liver toxicity. Methodology: Three groups of eighteen adult albino rats were randomly assigned: Control group had received D.W for 28 days, the second group got doxorubicin IP injection (2.5 milligrams per kilogram of body weigh t) on the 27th day, third group received vinpocetine orally at the dose (3 mg/kg /day) for 27 days. On the 27th day first give vinpocetine orally at the dose (3 mg/kg/day) and then give doxorubicin IP injection at the dose (2.5 mg/kg), after 28 days liver homogenate was prepared. Key Findings: The study's findings demonstrated that Doxorubicin induces cell injury causing significant rise in TNF-α levels, IL-1β, and CASP-3 and a decrease in IL-10 concentrations in liver homogenate tissues in comparison to the rats in group I as the control group. However, vinpocetine significantly ameliorated cell injury and suppressed cell apoptosis that doxorubicin induces and significantly decreases the expression of IL-1β and CASP-3 levels as well as it was raising IL-10 level when use in combination with doxorubicin in group II. Conclusion: The current study's findings vinpocetine inhibited doxorubicin induced apoptosis, cytokine production, which means that Vinpocetine possess role for reduction hepatotoxicity against liver damage induced by doxorubicin in rats. Recommendation: Study protective effect of vinpocetine and toxic effect of doxorubicin for other organs and evaluation other parameters.